IL145789A0 - Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them - Google Patents

Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL145789A0
IL145789A0 IL14578900A IL14578900A IL145789A0 IL 145789 A0 IL145789 A0 IL 145789A0 IL 14578900 A IL14578900 A IL 14578900A IL 14578900 A IL14578900 A IL 14578900A IL 145789 A0 IL145789 A0 IL 145789A0
Authority
IL
Israel
Prior art keywords
derivatives
preparation
pharmaceutical compositions
propionic acid
compositions containing
Prior art date
Application number
IL14578900A
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL145789A0 publication Critical patent/IL145789A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
IL14578900A 1999-04-20 2000-04-17 Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them IL145789A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900533 1999-04-20
PCT/DK2000/000190 WO2000063153A1 (en) 1999-04-20 2000-04-17 New compounds, their preparation and use

Publications (1)

Publication Number Publication Date
IL145789A0 true IL145789A0 (en) 2002-07-25

Family

ID=8094620

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14578900A IL145789A0 (en) 1999-04-20 2000-04-17 Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them

Country Status (16)

Country Link
EP (1) EP1171414A1 (en)
JP (1) JP2002542218A (en)
KR (1) KR20020005703A (en)
CN (1) CN1348439A (en)
AU (1) AU3958000A (en)
BR (1) BR0009864A (en)
CA (1) CA2367356A1 (en)
CZ (1) CZ20013558A3 (en)
HU (1) HUP0200807A3 (en)
IL (1) IL145789A0 (en)
NO (1) NO20015113L (en)
PL (1) PL351312A1 (en)
RU (1) RU2001131111A (en)
TW (1) TW553931B (en)
WO (1) WO2000063153A1 (en)
ZA (1) ZA200107983B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1396903A (en) * 2000-01-28 2003-02-12 诺沃挪第克公司 Novel compound, their preparation and use
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
ATE309818T1 (en) 2000-03-08 2005-12-15 Novo Nordisk As LOWERING SERUM CHOLESTEROL
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
WO2003011814A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
EP1414806A1 (en) * 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
MXPA04000891A (en) * 2001-07-30 2004-05-21 Novo Nordisk As Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
KR101116627B1 (en) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 Aryl carbonyl derivatives as therapeutic agents
RU2005109555A (en) 2002-09-05 2005-11-10 Ново Нордиск А/С (DK) NEW VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
BR0315683A (en) 2002-10-28 2005-08-30 Novo Nordisk As A compound, use thereof, pharmaceutical composition, and method for treating and / or preventing nuclear receptor mediated conditions and for treating and / or preventing type i diabetes, type ii diabetes, impaired glucose tolerance, resistance to insulin or obesity
CN100491316C (en) 2002-10-28 2009-05-27 高点制药有限责任公司 Novel compounds, their preparation and use
US7129268B2 (en) * 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
BR0315667A (en) * 2002-10-28 2005-09-06 Novo Nordisk As Compound, use of a compound, pharmaceutical composition, and method for treating
WO2004056740A1 (en) * 2002-12-20 2004-07-08 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
ES2378435T3 (en) 2003-09-19 2012-04-12 Janssen Pharmaceutica N.V. �? 4 - ((phenoxyalkyl) thio) -phenoxyacetic acids and the like
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
JP4865565B2 (en) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Controlling food selection using GLP-1 agonists
SI1723128T1 (en) 2004-01-06 2013-04-30 Transtech Pharma, Inc. Heteroaryl-ureas and their use as glucokinase activators
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
EP1745002B1 (en) * 2004-05-05 2010-11-03 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
CN101060856B (en) 2004-11-22 2011-01-19 诺和诺德公司 Soluble, stable insulin-containing formulations with a protamine salt
CA2590720A1 (en) 2004-12-03 2006-06-08 Lone Jeppesen Heteroaromatic glucokinase activators
FR2882359A1 (en) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S New phenyl compounds are peroxisome proliferator activated receptor activators useful to treat hyperlipidemia and atherosclerosis
EP1856072A4 (en) * 2005-02-25 2009-10-21 Seoul Nat Univ Ind Foundation Thiazole derivatives as ppar delta ligands and their manufacturing process
JP5121707B2 (en) 2005-07-04 2013-01-16 ハイ ポイント ファーマシューティカルズ，エルエルシー New medicine
ES2422383T3 (en) 2005-07-14 2013-09-11 Novo Nordisk As Urea glucokinase activators
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
ATE523497T1 (en) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc NEW 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES SUITABLE FOR THE TREATMENT OF OBESITAS AND DIABETES
CA2669874A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
BR112012024379A2 (en) 2010-03-26 2017-01-10 Novo Nordisk As "glucagon peptides, their use as well as pharmaceutical composition"
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd New oral dissolving films for insulin administration, for treating diabetes
AU2012234276A1 (en) 2011-03-28 2013-08-29 Novo Nordisk A/S Novel glucagon analogues
MX354705B (en) 2011-09-23 2018-03-16 Novo Nordisk As Novel glucagon analogues.
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN107915701B (en) * 2016-10-10 2020-09-29 沈阳药科大学 PPAR alpha/gamma dual agonist and application thereof
JP2020514365A (en) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス Bicyclic compound capable of binding to melanocortin 4 receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
IL300000A (en) 2020-07-22 2023-03-01 Reneo Pharmaceuticals Inc Crystalline ppar-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
ES2200248T3 (en) * 1997-09-19 2004-03-01 Ssp Co., Ltd. DERIVATIVES OF ACUDI FENILPROPIONICO REPLACED IN ALFA AND MEDICINAL PRODUCT CONTAINING THEM.
US6130214A (en) * 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
JP2002501909A (en) * 1998-01-29 2002-01-22 ドクター・レディーズ・リサーチ・ファウンデーション Novel alkanoic acid and its use in medicine, its production process and pharmaceutical composition containing it
DE69828445D1 (en) * 1998-04-23 2005-02-03 Reddys Lab Ltd Dr HETEROCYCLIC COMPOUNDS, AND THEIR USE IN MEDICAMENTS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
PL341795A1 (en) * 1998-05-27 2001-05-07 Reddy Research Foundation Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds

Also Published As

Publication number Publication date
WO2000063153A1 (en) 2000-10-26
CA2367356A1 (en) 2000-10-26
RU2001131111A (en) 2003-08-10
CN1348439A (en) 2002-05-08
EP1171414A1 (en) 2002-01-16
TW553931B (en) 2003-09-21
ZA200107983B (en) 2002-05-29
NO20015113D0 (en) 2001-10-19
CZ20013558A3 (en) 2002-05-15
NO20015113L (en) 2001-12-19
JP2002542218A (en) 2002-12-10
PL351312A1 (en) 2003-04-07
KR20020005703A (en) 2002-01-17
HUP0200807A3 (en) 2003-03-28
BR0009864A (en) 2002-01-08
HUP0200807A2 (en) 2002-07-29
AU3958000A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
IL145789A0 (en) Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them
HUP0200863A2 (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them and their use
HUP0105437A3 (en) Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
HUP0203509A3 (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
HUP9801044A3 (en) Sulfonylamino-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP9801045A3 (en) Sulfonyl-amino-carboxylic acid derivatives, use thereof, pharmaceutical compositions containing them and process for their preparation
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0204143A3 (en) Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them
HUP0200895A3 (en) Benzimidazole derivatives of alpha-substituted carboxylic acids, pharmaceutical compositions containing them and their use
HUP0102766A3 (en) Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them
IL145665A (en) Carbamic acid derivatives, their preparation and pharmaceutical compositions comprising them
HUP0201516A2 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201753A3 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202788A3 (en) Indolyl-3-glyoxylic acid derivatives serving as antitumor agents and pharmaceutical compositions containing them
HUP0000664A3 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use of them for producing pharmaceutical compositions
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
IL147282A0 (en) Novel aminothiazole derivatives, their preparation and pharmaceutical compositions containing them
HUP0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
PL352280A1 (en) Derivatives of naphthyridine, method of making same, use of same and pharmaceutical compositions containing these derivatives